News
CeNeRx, expecting trial results and drug partner in 2012, raises $4.8M
http://www.medcitynews.com/2011/12/cenerx-expecting-trial-results-and-drug-partner-in-2012-raises-4-
December 9, 2011
CeNeRx Biopharma completes $9 million financing
Download the PDF
June 15, 2009
CeNeRx BioPharma initiates Phase 2 clinical trial of its novel antidepressant agent Tyrima™
Download the PDF
October 17, 2008
CeNeRx BioPharma completes $15 Million Series B financing
Download the PDF
October 17, 2008
CeNeRx BioPharma to initiate Phase 2 trials for its novel antidepressant agent Tyrima™ using innovative brain imaging study
Download the PDF
July 22, 2008
CeNeRx BioPharma
Cary, NC
CeNeRx is developing innovative treatments for diseases of the central nervous system. Their lead product, a reversible inhibitor of monoamine oxidase, is in a Phase 2 trial for treatment resistant depression. CeNeRx also has a pipeline of selective cannabinoid compounds for the treatment of pain, glaucoma, and obesity.